Brent Rexer, MD
Medical Oncology · Nashville, TNNPI 1306896519
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $66 of the $99 with a category attached, or 66.7%. Daiichi Sankyo Inc. accounts for 66.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $66 and has fallen 68.2% since, to $21 in 2023. That places this record below the midpoint for medical oncology clinicians in TN, where the typical reported total is $6,231.
Across 3 payments — averaging $32.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$66
- Mirati Therapeutics, Inc.$21
- Gilead$12
Across 117 payments — averaging $11,188 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$528K
- AstraZeneca$360K
- Pfizer$212K
- Daiichi Sankyo Inc.$103K
- Genentech, Inc.$89K
- Eli Lilly$11K
- plus $7K from 1 others
What the payments were for
- Food & beverage$6667%
- Education$3333%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 1 | $66 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Gilead | 1 | $12 |
How this compares
$99 in reported general payments places this provider in the 10th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 124 | $1,873,258 |
| OrserduElacestrant Hcl | 28 | $627,564 |
| VerzenioAbemaciclib | 24 | $316,707 |
| Exemestane | 71 | $13,867 |
| Letrozole | 481 | $13,289 |
| Ondansetron Hcl | 56 | $2,857 |
| Anastrozole | 50 | $1,453 |
| Tamoxifen Citrate | 31 | $757 |
| Gabapentin | 25 | $490 |
| Prochlorperazine Maleate | 19 | $488 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $485 |
| Oxycodone Hcl | 23 | $484 |
| Alendronate Sodium | 45 | $408 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $266 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 16 | $189 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Nashville
- William PaoNashville$838K
- Dana ThompsonNashville$339K
- Robert RamirezNashville$321K
- Mace RothenbergNashville$318K
- Melissa JohnsonNashville$290K
- Cathy EngNashville$231K
- David SpigelNashville$167K
- Michael GibsonNashville$141K
- Jordan BerlinNashville$120K
- Vandana AbramsonNashville$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.